INTRANASAL ADMINISTRATION

• US 20150165139A1
• Filed: 03/02/2015
• Published: 06/18/2015
• Est. Priority Date: 06/08/2006
• Status: Active Grant

• Current Assignee: OptiNose, Inc.
• Original Assignee: OptiNose AS (OptiNose, Inc.)
• Inventors: HAFNER, Roderick Peter
• Granted Patent: US 10,112,021 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/1796 for hormones for neuromediators A61K38/1787
• CPC Class Codes: A61K 38/2228 Corticotropin releasing factor [CRF] (Urotensin)
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61M 15/0091 mechanically breath-triggered
• CPC Class Codes: A61M 15/0098 Activated by exhalation
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61M 2210/0618 Nose
• CPC Class Codes: A61M 2210/0625 Mouth
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region.

Claims

1. A method of delivering a protein formulation to the upper posterior region of a nasal cavity of a subject for uptake into the CNS of the subject, the method comprising the steps of delivering the formulation through a nozzle of a nosepiece of a delivery device into the nasal cavity of the subject to provide for uptake of the protein to the CNS without triggering an immune response, and the subject exhaling through a mouthpiece unit to cause closure of the oropharyngeal velum of the subject, wherein air exhaled from an exhalation breath is delivered through the nosepiece to entrain the protein formulation as delivered from the nozzle.

3. The method of claim 1, wherein the protein comprises a corticotrophic releasing hormone, such as corticorelin or a pharmaceutically-acceptable derivative or analogue thereof.

4. The method of claim 1, wherein the protein comprises a somatotrophic hormone receptor antagonist, such as pegvisomant or a pharmaceutically-acceptable derivative or analogue thereof.

5. The method of claim 1, wherein the protein comprises insulin or an insulin analogue.

2. A method of delivering a protein formulation to the upper posterior region of a nasal cavity of a subject for uptake into the CNS of the subject, the method comprising the steps of delivering the formulation through a nozzle of a nosepiece of a delivery device into the nasal cavity of the subject to provide for uptake of the protein to the CNS without triggering an immune response, and delivering a gas flow, separate to an exhaled air flow from an exhalation breath of the subject, to the nosepiece to entrain the protein formulation as delivered from the nozzle.